# Schistosome-derived microRNAs: promise, pitfalls and priorities for molecular diagnosis

## TL;DR

Schistosome microRNAs show promise for diagnosing schistosomiasis but face challenges in real-world use due to technical and infrastructural barriers.

## Contribution

The paper highlights the potential of schistosome-derived miRNAs for molecular diagnosis and outlines priorities for their translational development.

## Key findings

- Schistosome miRNAs are stable in host biofluids and reflect infection status and worm burden.
- Several miRNA candidates show high sensitivity and specificity across Schistosoma species.
- Field deployment is hindered by low detection sensitivity and lack of standardized workflows.

## Abstract

Schistosomiasis remains a major neglected tropical disease with persistent transmission despite decades of control programs. Recent discoveries of schistosome-derived microRNAs (miRNAs) have introduced new opportunities for precise, non-invasive molecular diagnosis. These miRNAs, often encapsulated in extracellular vesicles (EVs) or associated with Argonaute proteins, are stable in host biofluids and reflect active infection, worm burden, and pathological status. Therefore, this commentary aims to summarize current advances in schistosome-derived miRNAs for molecular diagnosis, discuss the major challenges limiting their field deployment, and propose future priorities for translational development.

Accumulating evidence from both experimental models and human studies supports the diagnostic value of schistosome-derived miRNAs, with several candidates demonstrating high sensitivity and specificity across Schistosoma species. However, despite this promise, translation to field applications remains limited. Major challenges include low detection sensitivity in low-intensity infections, lack of standardized reference materials, absence of harmonized workflows, and dependence on complex laboratory infrastructure. Structural barriers—such as insufficient policy support, weak diagnostic infrastructure, and global inequities in resource allocation—further constrain deployment in endemic regions. Bridging these gaps demands a shift from exploratory discovery to translational and equity-centered development.

In summary, although schistosome-derived microRNAs have demonstrated strong diagnostic potential across experimental and clinical settings, their impact remains limited by technological, infrastructural, and policy-related challenges, particularly in endemic regions. Future priorities should emphasize affordable, point-of-care diagnostic platforms, establishment of shared databases and international standards, and integration of molecular tools into national surveillance and elimination programs. Aligning technological innovation with accessibility and health equity will be crucial to transform schistosome miRNA biomarkers from laboratory findings into practical tools for global schistosomiasis control and elimination.